The B2B platform for the best purchasing descision. Identify and compare relevant B2B manufacturers, suppliers and retailers
Filter
Locations
Result types
Type of company
Select company type
Industries
Select industry
Company status
Select company status preset
Number of employees
Min.
Max.
Founding year
Lock keywords
Exclude keywords
Optional keywords
Esenler, Turkey
1-10 Employees
2016
We develop our products with researchers in tissue engineering and regenerative medicine fields. We develop our product to be powerful, fast and reliable, so you can do what you do best with our products with ease. We specialize in building and developing bioprinting platforms specific to your needs.
+
Featured
Tissue Engineering Devices
... We provide one of a kind tissue engineering solutions for researchers all around the world. ...
Houston, United States
1-10 Employees
2017
Materials are absorbed by the body, unlike alloy-based products. Dialysis is the primary lifeline for patients with end-stage renal disease, but dialysis access sites are prone to failure, reducing the quality and length of life for patients.
+
Featured
Company | VenoStent
... A Clinical-Stage Tissue Engineering ...
Milton Keynes, United Kingdom
11-50 Employees
2011
Cenobiologics Ltd provides a wide range of Allograft Bio-implants for human transplantation for any health care system and/or medical professionals. Cenobiologics Ltd is a Human Tissue Authority (HTA) Licensed member of the European Association of Tissue Banks (EATB). CenoBiologics adheres to strict guidelines, standards and disciplines issued and monitored by the HTA, to meet the European Union Tissues and Cells Directives (EUTCD). To accomplish our mission, the CenoBiologics team consists of highly dedicated and motivated individuals who are committed to finding solutions in order to achieve success. Our products are manufactured in a highly technological environment with a state of the art facility to obtain the best quality possible. Although we are proud of our products, we are always focussed on improving them, thus facilitating the development of the company. Also, we are participating in several cooperation and joint projects with universities and professionals. Our Bio-implants are processed, produced and supplied in a-state-of-the-art facility using the latest processing technologies.
+
Featured
CenoBiologics – Tissue Engineering
... CenoBiologics – Tissue Engineering ...
Victoria, Canada
1-10 Employees
2020
A new way forward in 3D bioprinting by creating Human-like tissue models. VoxCell BioInnovation originated from current technology limitations and the gap in the market for creating complex 3D bioprinted models, specifically in the area of tissue engineering and the drug development industry; existing 3D bioprinting technology is not capable of developing human-like models with high resolution and meaningful vasculature. Bioinks - Universal Bioinks™ Capable of Mimicking Multiple Soft Tissue Types. 3D Bioprinter - Ultra High-Resolution Bioprinter Used for the Creation of Human-Like Cancer Tissue Models. Tissue Models - Human-Like Cancer Tissue Models for Reliable Drug Screening.
+
Featured
REVOLUTIONIZING tissue engineering
... REVOLUTIONIZING tissue engineering ...
Oslo, Norway
1-10 Employees
2020
ClexBio is a pre-clinical stage regenerative medicine company with a breakthrough proprietary technology platform for scalable, high-throughput tissue generation.Our team brings highly relevant experience from the biotech industry and expertise in cell biology, tissue culture automation, and translational research from top academic institutions across Europe and the US. ClexBio is a pre-clinical stage regenerative medicine company with a breakthrough proprietary technology platform for scalable, high-throughput tissue generation.
+
Featured
ClexBio | Engineering Human Tissue Transplants
... ClexBio is a biotech company creating innovative solutions for tissue engineering and single-cell techniques using advanced microfluidics and the proprietary CLEX hydrogel technology. ...
Pembroke Dock, United Kingdom
1-10 Employees
2013
Founded in 2015, Jellagen is a UK-based biotechnology company that develops and manufactures medical grade Collagen Type 0 for use in tissue engineering and regenerative medicine. Jellagen develops Collagen Type 0 as an innovative biomaterial platform for a range of medical applications. Jellagen is led by a world-class team with experience across science, pharma, biotech, medical devices and investment banking. Jellagen operate out of a 10,000 square-foot R&D, manufacturing and commercial facility in Cardiff, Wales. Jellagen’s collagen-based innovation addresses complex tissue engineering and regenerative medical needs, helping to shape next-generation medical treatments alongside current and future scientific research. Through the application of its proprietary technologies and expertise in the field of collagen, Jellagen has built an extensive IP portfolio and substantial datasets demonstrating the unique advantages of its Collagen Type 0 over mammalian collagens for medical applications. We have top-spec laboratories, a class 7 clean room, and scalable manufacturing space all operating to ISO13485:2016 certification.
+
Featured
Product Development | Jellagen
... Collagen-based innovation that addresses complex tissue engineering and regenerative medical needs, helping to shape next-generation medical treatments alongside current and future scientific research. ...
Vienna, Austria
11-50 Employees
We are a CRO providing the highest level of quality and customer service in biosafety testing services. Offering a broad range of biosafety testing services for the following therapeutics:. Our strong commitment to scientific excellence, quality and customer service has established ViruSure as a preferred supplier for biopharmaceutical companies throughout the world. Hear our presentations and speak with our experts at these events.
+
Featured
Tissue Engineering
... Tissue engineering is an emerging multidisciplinary ATMP field that aims to repair, regenerate or replace human tissue. ...
Hillsborough Township, United States
1-10 Employees
2003
Bezwada Biomedical is proud to receive an NSF award on bioabsorbable tissue adhesive development. PLGA and Beyond PLGA for medical devices, drug delivery and regenerative medicine. Our absorbable polymers are used as bioinks, adhesion prevention barriers, absorbable drug eluting stent coatings, tissue adhesives and sealants, medical device coatings, drug delivery polymers, drug device combinations, absorbable implantable devices and tissue engineering biomaterial scaffolds. If you are ready to look beyond PLGA for superior fully tunable properties, get in touch to discuss your application requirements.
+
Featured
Tissue Engineering
... Tissue Engineering - Bezwada ...
Rome, Italy
1-10 Employees
1995
Its core business is the development of bioreactors for advanced cell culture and tissue engineering. Cellex is currently focused on the design, development and production of SUSPENCE®, a highly innovative scalable bioreactor that keeps cells in suspension in a culture chamber, allowing them to grow and reach maturity in dynamic conditions. The team responsible for the activities of CELLEX is a highly skilled and deeply experienced technical and commercial team. They are specialists in the field of medical technology, manufacturing, marketing, quality and regulatory management, project management and strategy, business management and communication. Founder and CEO of Cellex, is a Nuclear Engineer, PhD in Biomedical Engineering.
+
Featured
Development of bioreactors for advanced cell culture and tissue engineering.
... Development of bioreactors for advanced cell culture and tissue engineering. ...
Technologies which have been searched by others and may be interesting for you:
Some interesting numbers and facts about the results you have just received for Tissue Engineering
| Country with most fitting companies | United States |
| Amount of fitting manufacturers | 117 |
| Amount of suitable service providers | 71 |
| Average amount of employees | 1-10 |
| Oldest suiting company | 1995 |
| Youngest suiting company | 2020 |
Tissue engineering is a multidisciplinary field that combines the principles of life sciences and engineering to develop biological substitutes that restore, maintain, or improve tissue function or a whole organ. Central to this field is the use of a scaffold for the formation of new viable tissue for a medical purpose. This scaffold is designed to mimic the extracellular matrix of the native tissue, providing a three-dimensional space wherein cells can proliferate and differentiate into the desired tissue type. The process involves seeding these scaffolds with cells, possibly obtained from the patient (autologous cells) to minimize rejection risks, and subjecting them to conditions in bioreactors that replicate the physiological environment, fostering the development of functional tissue. The impact of tissue engineering is profoundly transformative, offering potential solutions for organ shortages in transplantation, repairing damaged tissues, and providing models for the study of disease and drug development. By enabling the creation of lab-grown organs and tissues, this field holds promise for personalized medicine, where treatments are tailored to the individual's own genetic makeup, significantly reducing the likelihood of transplant rejection and enhancing recovery outcomes. As such, tissue engineering stands at the forefront of biomedical research, heralding a future where regenerative medicine could become the standard for treating a wide array of previously incurable conditions.
1. Personalization and Compatibility
Tissue engineering offers the unique advantage of creating tissues or organs that are highly personalized and compatible with the patient's body. This significantly reduces the risk of rejection compared to traditional transplants, where the body may not accept foreign tissues.
2. Reduced Dependency on Donors
One of the most pressing issues in medical treatments involving organ transplants is the shortage of donors. Tissue engineering mitigates this problem by allowing for the lab-grown production of tissues and organs, thus reducing waiting times and saving more lives.
3. Enhanced Healing and Functionality
Tissues engineered in a lab can be designed to promote faster and more effective healing. They can also be tailored to improve the functionality of the damaged area, offering patients better outcomes compared to some of the alternative treatments that may not integrate as seamlessly with the body’s natural processes.
4. Advancement in Medical Research
Tissue engineering not only provides immediate benefits in terms of patient care but also paves the way for advancements in medical research. By studying engineered tissues, scientists can gain deeper insights into disease mechanisms and develop more effective treatments.
While evaluating the different suppliers make sure to check the following criteria:
1. Quality Certifications
Ensure the supplier has relevant certifications like ISO 13485 for medical devices, which demonstrates a commitment to quality and regulatory compliance.
2. Material Sourcing
Verify the origin and quality of materials used, as they must meet stringent safety and biocompatibility standards for tissue engineering applications.
3. Customization Capabilities
The supplier should offer customization options to meet specific research or clinical needs, including scaffold designs and material properties.
4. Technical Support and Collaboration
Assess the level of technical support provided, including consultation on product selection and customization, as well as potential for collaborative development projects.
5. Supply Chain Reliability
Consider the supplier's ability to consistently deliver high-quality products on time, including their inventory management and distribution efficiency.
6. Cost-Effectiveness
While not compromising on quality, evaluate the supplier's pricing structure to ensure it aligns with budgetary constraints and offers value for money.
Tissue engineering holds transformative potential across multiple industries, serving as a cornerstone for innovations in healthcare and beyond. In the medical sector, it plays a pivotal role in regenerative medicine, offering groundbreaking solutions for organ repair and replacement. By cultivating tissues and organs in the laboratory, healthcare providers can address the critical shortage of donor organs, significantly reducing waiting times for transplants and enhancing patient outcomes. Another significant application of tissue engineering is found within the pharmaceutical industry. Here, engineered tissues are utilized for drug testing and development, providing a more accurate and ethical alternative to animal testing. This approach not only accelerates the research and development process but also improves the safety and efficacy of pharmaceutical products by offering a human-relevant model for testing. In the realm of biotechnology, tissue engineering is instrumental in creating advanced biomaterials. These materials are designed to interact with biological systems, offering innovative solutions for wound healing, drug delivery systems, and even scaffolding for tissue regeneration. By leveraging the capabilities of tissue engineering, biotechnology firms can develop products that mimic natural tissue properties, leading to enhanced therapeutic applications and improved patient care. Collectively, these use cases underscore the versatility of tissue engineering and its capacity to revolutionize various industries through cutting-edge applications.
Tissue engineering, a pivotal branch of biomedical engineering, currently spans various Technology Readiness Levels (TRLs), generally ranging from TRL 4 to TRL 6. This variation reflects the field's ongoing transition from experimental laboratory research to preclinical and early clinical applications. At TRL 4, tissue engineering technologies are in the validation phase in a lab environment, where the basic biological feasibility is established using small-scale experiments. Progressing to TRL 5, these technologies undergo further validation under more realistic conditions, often involving larger-scale laboratory tests that mimic human physiological environments more closely. By TRL 6, tissue-engineered products or techniques are demonstrated in a relevant environment, typically through preclinical studies in animal models, which are crucial for assessing biocompatibility, efficacy, and safety before human trials. The positioning within these TRLs is primarily due to technical challenges such as replicating the complex microenvironment of native tissues, ensuring vascularization in engineered tissues for nutrient and waste exchange, and scaling up the production processes for clinical applications. Additionally, the integration of smart biomaterials and the incorporation of patient-specific cells through advances in 3D bioprinting are areas of intense research aiming to address these hurdles, gradually moving tissue engineering technologies towards higher TRLs.
In the Short-Term, advancements in tissue engineering are poised to enhance precision and efficiency in creating functional tissues. With the integration of 3D bioprinting technology, researchers will be able to fabricate tissues with higher cellular density and complexity. This phase is expected to see the development of more sophisticated biomaterials that better mimic the natural extracellular matrix, improving the survival and integration of engineered tissues into the human body. The Mid-Term phase will witness significant breakthroughs in vascularization and innervation of engineered tissues. As one of the current challenges, creating tissues with their own blood supply will be a focus, enabling the production of larger, more complex organs. This period will also see the emergence of smart biomaterials capable of responding to physiological conditions, promoting tissue healing and integration. Advances in stem cell technology will further empower tissue engineering, allowing for more personalized and effective therapeutic options. Looking into the Long-Term, the horizon of tissue engineering is expected to expand into the creation of fully functional organs for transplantation, drastically reducing the reliance on human donors. Breakthroughs in biofabrication methods will enable the production of organs with all necessary cell types and structures, seamlessly integrated into the patient's body. This era will also explore the regeneration of neurological tissues, offering hope for treating conditions like spinal cord injuries and neurodegenerative diseases, marking a new era in regenerative medicine.
